AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02173379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Description: * Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Study NCT02173379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE
Description: Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Study NCT00818740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
Study NCT03545620 — intervention group
Intervention type: DEVICE
Intervention: rescue technique
Description: which rescue technique will be preferred while established/predicted difficult airway/intubation occurs in the operation room after failed direct laryngoscopy
Study NCT02993965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine Reminder/Recall
Description: The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
Study NCT00183833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine, imatinib mesylate
Description: Capecitabine and imatinib mesylate will both be taken by mouth twice a day
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant Dimeglumine
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT01044992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
Study NCT04321122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound cyclo plasty
Description: The ultrasonic glaucoma treatment instrument produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast.
Study NCT03220997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitaflow Preload
Description: Carbohydrate loading drink
Study NCT02712164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified NPWT dressing
Description: Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
Study NCT02712164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm
Description: Standard of care for STSG donor sites.
Study NCT02712164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm
Description: Standard of care for STSG donor sites.
Study NCT01379456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: exercises, 20 sessions over 10 weeks
Study NCT02526186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Battlefield Auricular Acupuncture
Study NCT01884220 — intervention group
Intervention type: OTHER
Intervention: There are no interventions in this study.
Study NCT02907437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline as an add-on drug (200 mg/day)
Study NCT02907437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (200 mg/day)
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02732015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02732015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Hydrochloride
Description: Given PO
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02732015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00851188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet CBT self-help
Description: Internet based Cognitive behavioral self-help method for insomnia
Study NCT00851188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT self-help booklet
Description: Cognitive behavioral self-help method for insomnia via booklet
Study NCT00851188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Waiting list
Study NCT01421992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: One Tablet of methylphenidate, 20 mg per day during 3 weeks
Study NCT01421992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet placebo per day during 3 weeks
Study NCT02907437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: (450 mg/day)
Study NCT03525808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS
Description: Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.
Study NCT00904917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Intervention Project
Description: Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
Study NCT00904917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
Study NCT01082796 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glipizide
Description: Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
Study NCT04586465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin
Description: Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles
Study NCT03307187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GLB Adapted for Individuals with Impaired Mobility
Description: The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
Study NCT04247451 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Metabolic profile and nutritional goals in diabetic foot surgery patients
Description: Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants.
Study NCT01066793 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a [Pegasys]
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study NCT01066793 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2b [PegIntron®]
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study NCT03102671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of HeartHab application followed by usual care
Description: use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
Study NCT03102671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care followed by the use of HeartHab application
Description: Usual care (2 months) followed by the use of HeartHab application (two months)
Study NCT05033977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise (center-based)
Description: Exercise therapy with a physical therapist in a clinic.
Study NCT05033977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise (home-based)
Description: Patients did exercises at home every day and 3 times per day.
Study NCT04465656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serology test for COVID-19
Description: In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts:~1. ELISA test~2. Rapid Diagnostic tests (only if ELISA test is positive)
Study NCT03550547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational workshops
Description: 1 workshop : Knowledge of the pathology ; 2a workshop: Educational physical activity; 2b workshop : Educational physical activity; 4 workshop : Dietary; 5 workshop : Management of pain, fatigue and the medical treatments; 6 workshop : Articular hygiene and ergonomics; 7 workshop : Technical assistance, an adaptation of the living condition
Study NCT03550547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa Therapy
Description: Approved Spa therapy of knee osteoarthritis patients
Study NCT03550547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spa Therapy
Description: Approved Spa therapy of knee osteoarthritis patients
Study NCT03774394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
Study NCT03774394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
Study NCT03774394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel active metabolite
Description: In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
Study NCT03774394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel active metabolite
Description: In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
Study NCT05668572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
Description: 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30mcg, 40mcg, 60mcg, 40mcg, 20mcg, 20mcg, 20mcg, 20mcg and 20mcg, respectively, totaling 270mcg of antigens. A 3-dose regimen administered at months 0, 2 and 6.
Study NCT05668572 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
Description: 0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens
Study NCT00824707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 0.5mg per day
Study NCT00824707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy including protecting the liver function, anti-tumor and so on
Study NCT02376205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine hydrochloride 0.5% solution
Description: 10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
Study NCT02376205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: 10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
Study NCT02720159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Osseintegrated Prosthesis
Study NCT02907437 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: (450 mg/day)
Study NCT03124147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuroconn Eldith stimulator by Magstim
Description: Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
Study NCT03124147 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuroconn Eldith stimulator by Magstim
Description: Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
Study NCT00994214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIM 23A760
Description: Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
Study NCT01958398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promillekoll
Description: Smartphone app monitoring alcohol use with feedback.
Study NCT01958398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartyPlanner
Description: Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
Study NCT04013152 — intervention group
Intervention type: OTHER
Intervention: Clinical database
Description: Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
Study NCT01937715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
Study NCT01937715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
Study NCT01937715 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/m\^2 every 2 weeks or 7.5 mg/m\^2 every 3 weeks
Study NCT01937715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Full dose FOLFIRI regimen every 2 weeks
Study NCT01922856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTR192G with dscCfaE
Description: Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
Study NCT01922856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: Controls only receive challenge
Study NCT03435159 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Doppler Ultrasonography
Description: GE LOGIQ S8 ultrasound machine was used to measure blood flow parameters in right and left a. carotis communis, a. carotis interna and a. vertebralis. All vessels were examined in the axial plane through their traces in the B-mode with a C6-15 MHz curvilinear matrix probe. Flow patterns and directions of vessels were then examined with Colour Doppler and it was determined whether there was any stenosis. Intimal thickness of a. carotis communis was measured by spectral doppler method. Measurements were recorded by visualizing the CCA at the supraclavicular level, the ICA carotid sinus (C4 level), and the VA at the V2 segment (C3-4 level), with less angle at 60 degrees. All measurements before and after the application were made at the same level. Immediately after manipulation, blood flow parameters were recorded as numerical data by the same physician again with Doppler USG of the relevant arteries.
Study NCT03435159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Chiropractic Spinal Manipulation
Description: Manipulation procedures were applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Manual chiropractic manipulation for C1 vertebra was applied in sitting position, using the digit / atlas pull technique. This technique is applied with the contact of practitioner's middle finger to the posterior part of transverse process of atlas, and generate a rotation force between C1 and C2 vertebrae.~The procedure was applied to C2 vertebra using the index / facet push technique in the supine position. This technique places pushing force in the direction of rotation between the C2-C3 vertebrae, placing the practitioner's index finger in contact with the posterior surface of the C2 facet joint.